Haemophilia B: from molecular diagnosis to gene therapy.
Thanks to its typical expression, haemophilia can be identified in writings from the second century AD. Haemophilia B, an X-linked recessive bleeding disorder due to factor IX (FIX) deficiency, has an incidence of about 1:30,000 live male births. The factor 9 (F9) gene was mapped in 1984 on Xq27.1. Haemophilia is diagnosed from prothrombin time, activated partial thromboplastin time, and FIX levels. Carrier females are usually asymptomatic and must be identified only with molecular analysis. Linkage analysis of F9 polymorphisms is rapid and inexpensive but limited by non-informative families, recombinant events, and the high incidence of germline mutations; thus, various procedures have been used for the direct scan of F9 mutations. We set up a novel denaturing high performance liquid chromatographic procedure to scan the F9 gene. This rapid, reproducible procedure detected F9 mutations in 100% of a preliminary cohort of 18 haemophilia B patients. Parallel to the development of more efficient diagnostic tools, the life expectancy and reproductive fitness of haemophilic patients have greatly improved and will continue to improve thanks to the use of less immunogenic recombinant FIX. Hopefully, new approaches based on gene therapy now being evaluated in clinical trials will revolutionise haemophilia B treatment.
Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II and CEINGE-Biotecnologie avanzate, Napoli, Italy. castaldo@dbbm.unina.it
Giuseppe
G
Castaldo
Paola
P
Nardiello
Fabiana
F
Bellitti
Rita
R
Santamaria
Angiola
A
Rocino
Antonio
A
Coppola
Giovanni
G
di Minno
Francesco
F
Salvatore
D005164:Factor IX / Q000235:genetics; D015316:Genetic Therapy; D002836:Hemophilia B / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D006801:Humans
D005164:Factor IX